Skip to main content

Peer Review reports

From: When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan

Original Submission
4 Feb 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
25 Feb 2022 Reviewed Reviewer Report
9 Mar 2022 Reviewed Reviewer Report
7 Apr 2022 Author responded Author comments - Wen-Chien Cheng
Resubmission - Version 3
7 Apr 2022 Submitted Manuscript version 3
8 Apr 2022 Author responded Author comments - Wen-Chien Cheng
Resubmission - Version 4
8 Apr 2022 Submitted Manuscript version 4
18 Apr 2022 Reviewed Reviewer Report
4 May 2022 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
16 May 2022 Editorially accepted
23 May 2022 Article published 10.1186/s12885-022-09672-4

You can find further information about peer review here.

Back to article page